Figure 4.
Figure 4. Total IgG-secreting and anti-measles IgG-secreting cells in HIV infection. PBMCs from 8 HIV-negative controls, 9 PHI subjects, and 20 CHI subjects were stimulated for 6 days with a combination of CpG, anti-CD40 mAb, IL-2, and IL-10. Stimulated PBMCs were then added to ELISPOT plate wells precoated with goat anti-human IgG or measles antigen. Results are expressed as number of total IgG-secreting (A) or anti-measles IgG-secreting (B) cells per 106 stimulated PBMCs. (C) Percentages of measles-specific ASCs were determined by dividing the number of measles IgG-secreting cells by the number of total IgG-secreting cells in controls, patients with PHI, and patients with CHI. The ends of the boxes define the 25th and 75th percentiles, with a line at the median and error bars defining the 10th and 90th percentiles.

Total IgG-secreting and anti-measles IgG-secreting cells in HIV infection. PBMCs from 8 HIV-negative controls, 9 PHI subjects, and 20 CHI subjects were stimulated for 6 days with a combination of CpG, anti-CD40 mAb, IL-2, and IL-10. Stimulated PBMCs were then added to ELISPOT plate wells precoated with goat anti-human IgG or measles antigen. Results are expressed as number of total IgG-secreting (A) or anti-measles IgG-secreting (B) cells per 106 stimulated PBMCs. (C) Percentages of measles-specific ASCs were determined by dividing the number of measles IgG-secreting cells by the number of total IgG-secreting cells in controls, patients with PHI, and patients with CHI. The ends of the boxes define the 25th and 75th percentiles, with a line at the median and error bars defining the 10th and 90th percentiles.

Close Modal

or Create an Account

Close Modal
Close Modal